Ozempic vs Rybelsus vs Wegovy

Ozempic (semaglutide), Rybelsus (semaglutide), and Wegovy (semaglutide) are GLP-1 medications used for weight management or type 2 diabetes. Key differences: Ozempic is FDA-approved, Rybelsus is FDA-approved, Wegovy is FDA-approved.

Effectiveness varies by individual. In clinical trials, tirzepatide-based drugs (Mounjaro, Zepbound) produced ~22% average body-weight loss vs ~15% for semaglutide-based (Ozempic, Wegovy). Discuss with your prescriber.

Cheapest first, at a maintenance dose and paying cash: Ozempic $349/mo (0.25, 0.5 and 1 mg pen) direct from the manufacturer · Wegovy ~$349/mo for maintenance doses direct from the manufacturer · Rybelsus ~$968/mo at list price, with no manufacturer self-pay route we can verify. These are self-pay prices from the manufacturer, not list prices — the list price is what an uninsured walk-in is billed who asks for nothing, and it is the one figure almost nobody pays. Compounded semaglutide runs $99–$300/mo and compounded tirzepatide $179–$450/mo through telehealth, but neither is FDA-approved.